Compare XTNT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | ACRV |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 82.2M |
| IPO Year | 2009 | 2022 |
| Metric | XTNT | ACRV |
|---|---|---|
| Price | $0.47 | $1.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.00 | ★ $11.67 |
| AVG Volume (30 Days) | 150.9K | ★ 493.5K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,337,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.30 | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $1.05 |
| 52 Week High | $0.95 | $3.56 |
| Indicator | XTNT | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 40.40 |
| Support Level | $0.44 | $1.51 |
| Resistance Level | $0.67 | $1.86 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 19.73 | 7.61 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.